I apologize if this has been covered before, but I'm wondering to what extent Apabetalone and Vascepa might be in competition. If A is as good as we hope, does that doom or severely damage V's prospects? How much might V's success diminish A's prospects?

I suppose it's too much to hope that A and V would turn out to be complementary, although that would be wonderful for cardio patients.....